Brokerages Set Cellebrite DI Ltd. (NASDAQ:CLBT) Target Price at $16.70

Cellebrite DI Ltd. (NASDAQ:CLBT) has received an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $16.70.

A number of brokerages have weighed in on CLBT. Lake Street Capital lowered their price target on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Needham & Company LLC cut their price objective on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday, August 14th. DA Davidson reduced their target price on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Weiss Ratings lowered Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 27th. Finally, JPMorgan Chase & Co. dropped their price target on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $11.62 on Monday. The firm’s 50-day moving average is $14.12 and its 200-day moving average is $13.72. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of 52.82, a PEG ratio of 1.82 and a beta of 1.15. Cellebrite DI has a 52-week low of $9.58 and a 52-week high of $19.98.

Insider Activity at Cellebrite DI

In other news, CEO Thomas E. Hogan sold 139,713 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total value of $2,150,183.07. Following the transaction, the chief executive officer directly owned 790,548 shares of the company’s stock, valued at $12,166,533.72. This represents a 15.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CRO Marcus Jewell sold 12,562 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $11.24, for a total transaction of $141,196.88. Following the completion of the transaction, the executive directly owned 427,128 shares in the company, valued at $4,800,918.72. The trade was a 2.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 329,658 shares of company stock valued at $4,970,967 in the last ninety days. Company insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its position in Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares during the last quarter. CWM LLC grew its position in shares of Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares during the last quarter. SkyView Investment Advisors LLC grew its position in shares of Cellebrite DI by 2.6% in the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after purchasing an additional 970 shares during the last quarter. Alamea Verwaltungs GmbH increased its stake in shares of Cellebrite DI by 4.3% during the fourth quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock worth $444,000 after purchasing an additional 1,018 shares during the period. Finally, Pacer Advisors Inc. increased its stake in shares of Cellebrite DI by 45.1% during the fourth quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock worth $72,000 after purchasing an additional 1,238 shares during the period. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.